Press releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Nov 9, 2009COGNIS® CRT-D and TELIGEN® ICD are the world's smallest and thinnest high-energy devices
Boston Scientific Corporation (NYSE: BSX) today announced the launch of its COGNIS® cardiac resynchronization therapy defibrillator (CRT-D) and...
-
Nov 6, 2009Company updates third quarter financial results and full-year 2009 guidance
Boston Scientific Corporation (NYSE: BSX) today announced that it has reached an agreement in principle with the U.S. Department of Justice (DOJ)...
-
Nov 2, 2009Third-generation drug-eluting stent now available in CE Mark countries
Boston Scientific Corporation (NYSE: BSX) today announced it has received CE Mark for its PROMUS® Element™ Everolimus-Eluting Coronary Stent...
-
Oct 19, 2009
Boston Scientific Corporation (NYSE: BSX) today announced financial results for the third quarter ended September 30, 2009, as well as guidance for...
-
Oct 9, 2009
Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results for the third quarter ended September 30,...
-
Oct 6, 2009Three models of stenting system now available for palliative treatment of malignant common bile duct strictures
Boston Scientific Corporation (NYSE: BSX) today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to...
-
Oct 5, 2009
Boston Scientific Corporation (NYSE: BSX) today announced its exclusive sponsorship and first enrollments of the MADIT-RIT clinical trial. This new...
-
Sep 29, 2009
Boston Scientific Corporation (NYSE: BSX) today announced the settlement of more than a dozen lawsuits involving Johnson & Johnson, including the...
-
Sep 25, 2009
Boston Scientific Corporation (NYSE: BSX) today announced two-year follow-up data from the HORIZONS-AMI trial. The trial,...
-
Sep 23, 2009Results support benefits of paclitaxel-eluting stents in diabetic patients
Boston Scientific Corporation (NYSE: BSX) today welcomed one-year data from the SPIRIT IV clinical trial comparing the XIENCE...
-
Sep 22, 2009Three-year TAXUS ATLAS results show safety and efficacy advantages for Boston Scientific TAXUS Liberte Stent
Boston Scientific Corporation (NYSE: BSX) today announced comprehensive data from the TAXUS ATLAS clinical program, a series of...
-
Sep 21, 2009Both drug-eluting stents performed well in diabetic patients
Boston Scientific Corporation (NYSE: BSX) today welcomed three-year results from the SPIRIT III clinical trial, which continue...
-
Sep 21, 2009
Boston Scientific Corporation (NYSE: BSX) today announced release of its CE-Marked, next-generation iLab System Software for the iLab® Ultrasound...
-
Sep 18, 2009PLATINUM clinical program to support FDA approval of PROMUS® Element™ Stent
Boston Scientific Corporation (NYSE: BSX) today announced the completion of patient enrollment in the workhorse portion of its PLATINUM clinical...
-
Sep 16, 2009
Boston Scientific Corporation (NYSE: BSX) today announced the schedule of the Company's major events and press announcements at the Cardiovascular Research...
-
Sep 14, 2009Boston Scientific's Urology/Gynecology Business Forms Marketing Alliance with Bladder Health NetworkAgreement promotes access to testing solutions for female urinary incontinence
Boston Scientific Corporation (NYSE: BSX) today announced that it has entered into a co-marketing agreement with Bladder Health Network, a...
-
Sep 10, 2009
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Morgan Stanley Global Healthcare Conference, September 14-15. Ray...
-
Sep 4, 2009
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Thomas Weisel Partners 2009 Health Care Conference, September 9 - 11....
-
Sep 2, 2009
Boston Scientific Corporation (NYSE: BSX) today announced two-year data from its SYNTAX clinical trial comparing percutaneous...
-
Sep 1, 2009
Boston Scientific Corporation (NYSE: BSX) today announced long-term data from the Prevention of Sudden Cardiac Death II registry...
-
Sep 1, 2009Results of landmark heart failure trial published by New England Journal of Medicine and presented at ESC
Boston Scientific Corporation (NYSE: BSX) today announced final results from the landmark MADIT-CRT trial, which were published by the...
-
Aug 31, 2009Dr. Ken Stein to join CRM group
Boston Scientific Corporation (NYSE: BSX) today announced that Ken Stein, M.D., FACC, will join the Company as Senior Vice President and Associate...
-
Aug 27, 2009
Boston Scientific Corporation (NYSE: BSX) today announced the schedule of the Company's major events and news announcements for the European...
-
Aug 26, 2009
The statement below is from Pete Nicholas, Chairman of the Board of Boston Scientific Corporation, on behalf of the Company, its employees and its Board of...
-
Aug 24, 2009
Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing final results from the landmark MADIT-CRT trial on Tuesday,...